Amgen, Inc. (AMGN) Shares Bought by Fisher Asset Management LLC
Fisher Asset Management LLC raised its position in shares of Amgen, Inc. (NASDAQ:AMGN) by 2.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 129,392 shares of the medical research company’s stock after purchasing an additional 2,855 shares during the period. Fisher Asset Management LLC’s holdings in Amgen were worth $24,125,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Financial Advisory Service Inc. raised its position in shares of Amgen by 0.3% in the 2nd quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock worth $340,000 after acquiring an additional 5 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its position in shares of Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after acquiring an additional 5 shares in the last quarter. Capital Advisors Ltd. LLC raised its position in shares of Amgen by 0.6% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock worth $190,000 after acquiring an additional 7 shares in the last quarter. Ballentine Partners LLC raised its position in shares of Amgen by 0.3% in the 2nd quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock worth $620,000 after acquiring an additional 9 shares in the last quarter. Finally, Hudock Capital Group LLC raised its position in shares of Amgen by 0.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock worth $330,000 after acquiring an additional 10 shares in the last quarter. 78.46% of the stock is owned by institutional investors and hedge funds.
In other news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. Insiders sold 8,575 shares of company stock worth $1,509,339 in the last 90 days. Company insiders own 0.19% of the company’s stock.
Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The firm had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. During the same quarter in the prior year, the business earned $3.02 earnings per share. The company’s revenue was down .7% compared to the same quarter last year. research analysts expect that Amgen, Inc. will post 12.66 EPS for the current fiscal year.
Amgen announced that its Board of Directors has approved a share repurchase program on Wednesday, October 25th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s leadership believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be paid a $1.32 dividend. This is an increase from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date is Wednesday, February 14th. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.99%. Amgen’s dividend payout ratio is presently 41.55%.
Several research firms have recently commented on AMGN. Citigroup lowered Amgen to a “neutral” rating in a research report on Monday. Goldman Sachs Group lowered Amgen from a “conviction-buy” rating to a “buy” rating in a research report on Friday, December 15th. Oppenheimer set a $205.00 price target on Amgen and gave the stock a “buy” rating in a research report on Tuesday, December 12th. BidaskClub raised Amgen from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 2nd. Finally, Cann reaffirmed a “buy” rating and set a $205.00 target price on shares of Amgen in a research report on Thursday, November 30th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Amgen currently has an average rating of “Hold” and a consensus target price of $190.22.
TRADEMARK VIOLATION WARNING: “Amgen, Inc. (AMGN) Shares Bought by Fisher Asset Management LLC” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/amgen-inc-amgn-shares-bought-by-fisher-asset-management-llc/1773924.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.